See how your reported results read as versioned evidence records β linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review claims
Explore by Goal
"We cannot solve our problems with the same thinking we used when we created them."
- Albert Einstein
Quick Explanation
Copied
Masaharu Murata β scientific profile
Evidence quality is best supported in the supplied dataset by a mechanistic mouse+human endothelial study linking ADSC-exosome effects to miR-126 β PI3K/Akt signaling, but the evidence shows typical translation gaps (mouse histone model, limited group sizes, exosome-prep uncertainty). Key anchor paper:10.1186/s13287-020-02015-9.
Long Explanation
Author Review: Masaharu Murata
Skeptical, evidence-based critique focused on the biological/scientific strength of the authorβs work using: (i) supplied author-level metrics and (ii) the supplied raw-data extract for a single full-text-linked study.
Top match: Masaharu Murata β works_count=136, cited_by_count=2927, h_index=26.
Other matches exist (name ambiguity risk): OpenAlex returns multiple βMasaharu Murataβ variants with different h-indices, suggesting potential conflation across individuals.
User-provided local author record shows only 2 papers with very small counts (h-index=1; total citations=5), which is inconsistent with the larger OpenAlex matchβanother strong ambiguity/red-flag about identity resolution.
Methodological caution: citation metrics alone do not establish mechanistic truth; they can reflect topic popularity, institution visibility, and co-authorship. Also, name disambiguation errors can inflate/deflate inferred impact.
2) Productivity & attention over time (provided counts_by_year)
Plotting the provided OpenAlex βcounts_by_yearβ series. This is a descriptive signal, not proof of scientific rigor.
3) Deep dive into the supplied full-text raw-data extract (single anchor study)
The most concrete scientific evidence available in your prompt is a mechanistic study about ADSC-derived exosomes protecting against histone-induced acute lung injury via miR-126 and PI3K/Akt signaling. Below, I extract what is explicitly present in the provided raw-data fields and critically assess the internal logic and limitations.
Study type and key mechanistic claims are explicitly described in the provided extract. I will therefore cite the full paper DOI for all mechanistic statements.
Important: The visualization uses only the ordinal direction explicitly described in your provided extract: β~50% mortality within 1 hβ, β100% survival at 6 hβ, and βabrogated/reduced protectionβ when exosome release or PI3K/Akt is inhibited. The plot is intentionally not presented as exact survival proportions.
4) Mechanistic chain assessment (what is known vs uncertain)
Known (supported by provided raw-data fields)
In vivo model: male C57BL/6N mice received i.v. calf thymus histones (75 mg/kg) with/without ADSCs; endpoints at ~6 hours include survival and vascular permeability.
ADSC/exosome dependence: ADSCs improved survival and reduced histone-induced endothelial injury; inhibiting exosome release (GW4869) or blocking PI3K/Akt signaling (LY294002) diminished the protection.
Pathway engagement: histone exposure with ADSC treatment increased endothelial phospho-Akt; GW4869 and LY294002 reduced this increase.
miR-126 involvement: histone exposure increased miR-126 in ADSCs and in ADSC-derived exosomes; manipulating miR-126 in ADSCs altered endothelial viability and PI3K/Akt activation.
All of the above are taken directly from the provided extract for 10.1186/s13287-020-02015-9.
Uncertain / could change with better controls or deeper validation
Exosome preparation specificity: the extract states exosome isolation used ExoQuick-TC, which can co-precipitate non-exosomal materialβso βexosomesβ vs βother vesicles/co-isolatesβ may not be perfectly separable.
Model translation gap: calf thymus histones infusion is not identical to endogenous histone release patterns in clinical sepsis/ARDS.
Group sizes / statistical power: several in vivo assays have small N; power and effect-size stability may be limited.
Randomization/blinding: the extract says explicit randomization/blinding details were not provided.
Causality granularity: while miR-126 is strongly implicated, other exosomal cargos/pathways may contribute and were not fully exhausted in the provided extract.
These limitations are explicitly stated in the provided extract for 10.1186/s13287-020-02015-9.
This plot only reflects the provided extract statement that histone exposure increases miR-126 in ADSCs and in derived exosomes; it does not show fold-changes.
5) Epistemic critique: what the evidence does (and does not) prove
Strengths (science-specific)
Multi-level evidence: the extract describes concordant signals across in vivo outcomes (survival, permeability) and in vitro endothelial mechanisms (viability, phospho-Akt, apoptosis marker).
Mechanistic perturbations: inhibitors targeting exosome release and PI3K/Akt are used to test pathway dependence.
Cargo manipulation: miR-126 gain/loss-of-function is used to link the exosomal cargo to endothelial signaling and survival.
Fragilities / likely failure modes
Attribution risk: if co-precipitated non-exosomal material contributes, GW4869/exosome-labeling interventions might not cleanly map to βexosomesβ alone.
Pathway non-specificity: pharmacologic inhibitors can have off-target effects (explicitly flagged in the extract).
Short horizon: 6-hour endpoints in an acute injury model can miss delayed harmful or protective dynamics.
Translation: even a correct mechanistic chain in mice may not generalize to human sepsis/ARDS with different histone dynamics and immune contexts.
6) What I could NOT verify from your provided inputs
I could not verify the full paper text beyond the supplied raw-data fields.
I could not assess reproducibility details (exact randomization/blinding implementation, replication across independent labs) beyond what is stated in the extract.
I did not analyze the other listed Murata works because only one DOIβs raw-data extract was provided in your prompt.
7) Practical next step (BGPT workflow)
If you want a stronger author-grade than βone anchor paper,β we should pull the full-text raw results for the authorβs top cited and most mechanistic works and run cross-paper falsification/consistency checks.
Feedback:
Updated: March 28, 2026
BGPT Author Review
Scientific Quality
60%
The provided evidence shows mechanistic depth in at least one well-described in vivo + in vitro study (perturbations at exosome release, PI3K/Akt, and miR-126). However, the provided material also highlights common fragilities (small group sizes in some assays, exosome prep specificity concerns, possible inhibitor off-targets, and a short acute endpoint with translational gaps). Additionally, the author identity ambiguity in the provided metrics (multiple Murata matches) limits confidence in mapping impact to a single individual.
Communication Quality
70%
Based on the provided extract, the mechanistic narrative is coherent and includes methods, models, interventions, and explicit limitations. Still, the extract itself doesnβt demonstrate full prose clarity across multiple works; also missing explicit randomization/blinding details would reduce clarity for a rigorous readers.
Author Novelty
70%
The mechanistic framing (ADSC-exosome β miR-126 β PI3K/Akt β endothelial protection) is plausible and aligned with known biology, but the extract does not establish whether the novelty is primarily the cargo identity, the specific injury model, or the particular pathway linkage; novelty canβt be fully judged without additional works.
Scientific Rigor
60%
There is evidence of causal testing via pathway and cargo perturbation, plus multiple readouts. Rigor is reduced by the limitations flagged in the provided extract: exosome isolation method uncertainty (co-precipitation), inhibitor off-target risk, small N in some experiments, missing explicit randomization/blinding details, and reliance on a histone infusion model with translation uncertainty.
Extract and tabulate the anchor paperβs experimental groups, interventions, outcomes, and limitations; then compute an ordinal mechanistic dependency map linking exosome inhibition, PI3K/Akt inhibition, and miR-126 manipulation.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The observed protection could be driven mainly by non-exosomal contaminants co-isolated by the precipitation method; if so, orthogonal vesicle isolation methods would abolish miR-126 dependence.
The PI3K/Akt inhibitor effects might reflect broad cytotoxicity or signaling disruption unrelated to ADSC-derived cargo; if so, downstream signaling readouts should show non-specific suppression across unrelated endothelial stressors.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion